Motus GI to Participate in Two Upcoming Investor Conferences in March 2022

Rhea-AI Summary

Motus GI Holdings, a medical technology company specializing in endoscopy solutions, announced its participation in two key investor conferences in March 2022. The first event is the 32nd Annual Oppenheimer Healthcare Conference from March 15 to 17, where management will engage with investors. The second conference is the LSI Emerging Medtech Summit from March 16 to 18, featuring a presentation on March 16 at 10:40 am PST. Interested investors can contact representatives for meetings.

FORT LAUDERDALE, Fla., March 02, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that its management team is scheduled to participate in two upcoming investor conferences in March 2022.

Event:	32nd Annual Oppenheimer Healthcare Conference
Conference Date:	Tuesday, March 15 – Thursday, March 17, 2022

Management will also meet with investors during the event. Investors interested in meeting with the Motus GI management team during the conference should contact their Oppenheimer & Co. representative.

Event:	LSI Emerging Medtech Summit
Conference Date:	Wednesday, March 16 – Friday, March 18, 2022
Presentation:	Wednesday, March 16, 2022 at 10:40 am PST

Management will also meet with investors during the event. Investors interested in meeting with the Motus GI management team during the conference should contact the Motus GI Investor Relations team.

About Motus GI
Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions.

For more information, visit www.motusgi.com and connect with the Company on Twitter, LinkedIn and Facebook.

Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the exercise of the warrants, the use of proceeds, the Company’s product development and commercialization, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential, “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or the Company’s financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Contact:
Bob Yedid
LifeSci Advisors
(646) 597-6989
bob@lifesciadvisors.com

FAQ

What conferences is Motus GI participating in March 2022?

Motus GI is participating in the 32nd Annual Oppenheimer Healthcare Conference from March 15 to 17 and the LSI Emerging Medtech Summit from March 16 to 18.

When will Motus GI present at the LSI Emerging Medtech Summit?

Motus GI's presentation at the LSI Emerging Medtech Summit is scheduled for March 16, 2022, at 10:40 am PST.

How can investors meet with Motus GI management during the conferences?

Investors interested in meeting with the Motus GI management team during the conferences should contact their Oppenheimer & Co. representative or the Motus GI Investor Relations team.

What type of company is Motus GI?

Motus GI is a medical technology company that provides endoscopy solutions aimed at improving clinical outcomes and enhancing cost-efficiency in diagnosing gastrointestinal conditions.